Literature DB >> 18724277

The role of registries in facilitating clinical research in BMT: examples from the Center for International Blood and Marrow Transplant Research.

Mm Horowitz1.   

Abstract

Observational databases, such as those maintained by the Center for International Blood and Marrow Transplant Research (CIBMTR) and the European Blood and Marrow Transplant Group (EBMT), play an important role in facilitating research into hematopoietic SCT (HCT) outcomes. The CIBMTR maintains a large database of the outcome of BMTs performed in 450 centers in 47 countries, including information on 240,000 transplant recipients and adding information on about 14,000 new transplants per year. The database has data for 9000 survivors followed for 10 or more years. The database may facilitate the understanding of outcomes by addressing questions difficult to answer through clinical trials. Clinical databases may also aid the development of optimal designs for prospective clinical trials. Use of the CIBMTR database for trial design and monitoring is an integral part of the US Blood and Marrow Transplant Clinical Trials Network (BMT CTN). The establishment of international outcomes registries was an important component of advances in HCT over the past three decades. Future progress will be further enhanced by inter-registry collaboration through the Worldwide Blood and Marrow Transplant Group (WBMT).

Mesh:

Year:  2008        PMID: 18724277     DOI: 10.1038/bmt.2008.101

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  38 in total

1.  Hematopoietic stem cell transplantation: a global perspective.

Authors:  Alois Gratwohl; Helen Baldomero; Mahmoud Aljurf; Marcelo C Pasquini; Luis Fernando Bouzas; Ayami Yoshimi; Jeff Szer; Jeff Lipton; Alvin Schwendener; Michael Gratwohl; Karl Frauendorfer; Dietger Niederwieser; Mary Horowitz; Yoshihisa Kodera
Journal:  JAMA       Date:  2010-04-28       Impact factor: 56.272

2.  Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data).

Authors:  Yoshiko Atsuta
Journal:  Int J Hematol       Date:  2015-11-07       Impact factor: 2.490

3.  Comparison of Methods for Identification of Pediatric Severe Sepsis and Septic Shock in the Virtual Pediatric Systems Database.

Authors:  Robert B Lindell; Akira Nishisaki; Scott L Weiss; Fran Balamuth; Danielle M Traynor; Marianne R Chilutti; Robert W Grundmeier; Julie C Fitzgerald
Journal:  Crit Care Med       Date:  2019-02       Impact factor: 7.598

Review 4.  Transplantation immunology: solid organ and bone marrow.

Authors:  Javier Chinen; Rebecca H Buckley
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

5.  Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.

Authors:  Betty K Hamilton; Ying Liu; Michael T Hemmer; Navneet Majhail; Olle Ringden; Dennis Kim; Luciano Costa; Robert Stuart; Amin Alousi; Joseph A Pidala; Daniel R Couriel; Mahmoud Aljurf; Joseph H Antin; Christopher Bredeson; Jean-Yves Cahn; Mitchell Cairo; Sung Won Choi; Christopher Dandoy; Robert Peter Gale; Usama Gergis; Peiman Hematti; Yoshihiro Inamoto; Rammurti T Kamble; Margaret MacMillan; David I Marks; Eneida Nemecek; Taiga Nishihori; Ayman Saad; Bipin N Savani; Jeff Schriber; Sachiko Seo; Gérard Socié; Takanori Teshima; Leo F Verdonck; Edmund K Waller; Mona Wirk; Stephen R Spellman; Mukta Arora; Saurabh Chhabra
Journal:  Biol Blood Marrow Transplant       Date:  2019-05-31       Impact factor: 5.742

Review 6.  Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts.

Authors:  M Aljurf; J D Rizzo; M Mohty; F Hussain; A Madrigal; M C Pasquini; J Passweg; N Chaudhri; A Ghavamzadeh; H E Solh; Y Atsuta; J Szer; Y Kodera; D Niederweiser; A Gratwohl; M M Horowitz
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

7.  Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research.

Authors:  Christopher Strouse; Paul Richardson; Grant Prentice; Sandra Korman; Robin Hume; Bijan Nejadnik; Mary M Horowitz; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-19       Impact factor: 5.742

8.  Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?

Authors:  Mitchell Sabloff; Ronald M Sobecks; Kwang Woo Ahn; Xiaochun Zhu; Marcos de Lima; Jennifer R Brown; Yoshihiro Inamoto; H Kent Holland; Mahmoud D Aljurf; Mary J Laughlin; Rammurti T Kamble; Jack W Hsu; Baldeep M Wirk; Matthew Seftel; Ian D Lewis; Mukta Arora; Edwin P Alyea; Matt E Kalaycio; Jorge Cortes; Richard T Maziarz; Robert Peter Gale; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-07       Impact factor: 5.742

9.  Graft-versus-host disease and survival after cord blood transplantation for acute leukemia: a comparison of Japanese versus White populations.

Authors:  Yachiyo Kuwatsuka; Yoshiko Atsuta; Mary M Horowitz; Jiro Inagaki; Junya Kanda; Koji Kato; Katsuyoshi Koh; Mei-Jie Zhang; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-10       Impact factor: 5.742

10.  Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis.

Authors:  Jack W Hsu; John R Wingard; Brent R Logan; Pintip Chitphakdithai; Gorgun Akpek; Paolo Anderlini; Andrew S Artz; Chris Bredeson; Steven Goldstein; Gregory Hale; Peiman Hematti; Sarita Joshi; Rammurti T Kamble; Hillard M Lazarus; Paul V O'Donnell; Michael A Pulsipher; Bipin N Savani; Raquel M Schears; Bronwen E Shaw; Dennis L Confer
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-12       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.